What is Prenetics?
Founded in 2014 and listed on Nasdaq, Prenetics operates internationally across the United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. The company's core offerings encompass consumer genetic testing, early colorectal cancer screening, COVID-19 testing solutions, rapid point-of-care diagnostics, at-home diagnostic testing, and comprehensive medical genetic testing services. By leveraging its mobile app and advanced technological platforms, Prenetics is dedicated to decentralizing healthcare, ensuring diagnostic services are available to anyone, anytime, and anywhere. This focus on accessibility and comprehensive genetic solutions positions Prenetics as a key player in the preventative and personalized healthcare market.
How much funding has Prenetics raised?
Prenetics has raised a total of $82.7M across 4 funding rounds:
Angel/Seed
$2.6M
Series A
$10M
Series B
$40M
Other Financing Round
$30M
Angel/Seed (2014): $2.7M with participation from Coent Venture Partners, SXE Ventures, and 500.com
Series A (2016): $10M led by COENT Venture, Venturra, Ping An, Capital Union Investments, Lippo Group, and 500.com
Series B (2017): $40M supported by Beyond Ventures, Venturra, and Ping An Ventures
Other Financing Round (2024): $30M featuring Insighta
Key Investors in Prenetics
Insighta
Insighta is an analytics company specializing in marketing measurement and advanced analytics, providing businesses with comprehensive visibility into advertising performance and predictive customer lifetime value insights. Their platform features a unified source of truth for revenue and ad spend, leveraging advanced multi-touch attribution and lifetime value integration to offer actionable insights.
COENT Venture
COENT provides seed and venture-stage funding to brilliant entrepreneurs and companies across all sectors in Asia. We back these entrepreneurs and companies with unparalleled support in funding, management, overseas business development and exposure to our network.
Venturra
Venturra is a Southeast Asia-focused venture capital firm that invests in early-stage, high-growth technology-enabled businesses. The firm aims to support companies with the ambition to redefine industries and drive significant change.
What's next for Prenetics?
The substantial enterprise-level funding Prenetics has garnered, particularly the recent strategic investment, signals a pivotal growth phase for the company. This capital infusion is expected to accelerate the expansion of its diagnostic and genetic testing services globally, further enhancing its technological infrastructure and market reach. Prenetics is poised to deepen its impact on preventative healthcare, potentially exploring new service lines or strategic partnerships to solidify its leadership in personalized medicine and accessible diagnostics. The company's continued focus on innovation and global accessibility suggests a future of sustained growth and influence within the health-tech industry.
See full Prenetics company page
